A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination
出版年份 2014 全文链接
标题
A dose-ranging study of MF59®-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination
作者
关键词
-
出版物
Human Vaccines & Immunotherapeutics
Volume 10, Issue 8, Pages 2395-2407
出版商
Informa UK Limited
发表日期
2014-06-20
DOI
10.4161/hv.29393
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant
- (2012) Murdo Ferguson et al. JOURNAL OF INFECTIOUS DISEASES
- Dose-range Study of MF59-adjuvanted Versus Nonadjuvanted Monovalent A/H1N1 Pandemic Influenza Vaccine in Six- to Less Than Thirty-Six-month-old Children
- (2012) Stan L. Block et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to ,9 Years of Age
- (2012) Cynthia Nassim et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects
- (2012) Hiroyuki Fukase et al. VACCINE
- A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects
- (2012) Christoph Hatz et al. VACCINE
- A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations
- (2012) Christoph Hatz et al. VACCINE
- Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older
- (2012) Hideyuki Ikematsu et al. Human Vaccines & Immunotherapeutics
- Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly
- (2012) Roberto Gasparini et al. Human Vaccines & Immunotherapeutics
- Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials
- (2011) François Roman et al. Clinical and Vaccine Immunology
- Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age
- (2011) Adriano Arguedas et al. Human vaccines & immunotherapeutics
- Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations
- (2011) Angelika Banzhoff et al. Human vaccines & immunotherapeutics
- Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children
- (2011) Timo Vesikari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines
- (2011) Lamberto Manzoli et al. PLoS One
- Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy: A six-month update
- (2011) Antonio Crucitti et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy
- (2011) Theodore F. Tsai et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines
- (2011) S. Khurana et al. Science Translational Medicine
- AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age
- (2010) François Roman et al. CLINICAL INFECTIOUS DISEASES
- MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk
- (2010) Paolo Durando et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence
- (2010) T. Vesikari et al. PEDIATRICS
- MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
- (2009) Angelika Banzhoff et al. PLoS One
- Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine
- (2009) G. Galli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
- (2009) G. Galli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages
- (2009) B. Camilloni et al. VACCINE
- MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database
- (2009) Michele Pellegrini et al. VACCINE
- MF59® -adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
- (2008) Angelika Banzhoff et al. Influenza and Other Respiratory Viruses
- Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults
- (2008) David I. Bernstein et al. JOURNAL OF INFECTIOUS DISEASES
- Safety of MF59™ adjuvant
- (2008) Viola Schultze et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now